Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06888102 · ClinicalTrials.gov registry record · Early Phase 1

A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer

A Early Phase 1 study of High-risk Prostate Cancer, sponsored by Edwin Posadas, MD.

Recruiting
Registry status
Early Phase 1
Development phase
20
Enrollment target
1
Study location

NCT06888102: Recruiting Early Phase 1 study of High-risk Prostate Cancer, sponsored by Edwin Posadas, MD.

NCT06888102 is a Early Phase 1 study of High-risk Prostate Cancer that is actively recruiting participants, run by Edwin Posadas, MD. The registered enrollment target is 20 participants, below the 54-participant average among 4 other High-risk Prostate Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06888102, a Early Phase 1 study of High-risk Prostate Cancer, is actively recruiting participants, sponsored by Edwin Posadas, MD.

RECRUITING
Registry status
Early Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of the underlying tumor to the patient's immune system. The platform study will evaluate safety, biomarkers, and clinical activity of an epigenetic therapy. The particular details relevant to each module within this platform study will be provided as appendices to the core protocol.

Primary Outcome

Safety and tolerability using CTCAE version 5.0. To assess the safety, toxicity, and feasibility of using epigenetic therapy in the neoadjuvant setting for men undergoing radical prostatectomy (RP). Defined by the number of patients who demonstrate treatment related AEs, defined as grade 3 or 4, or grade 2 that causes a dose interruption.

Conditions Studied

High-risk Prostate Cancer

Interventions

  • DRUG Neoadjuvant Epigenetic Therapy

Study Locations (1)

California

  • Cedars-Sinai Cancer at SOCC - Los Angeles

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2026-04
Est. Completion 2029-10
Phase Early Phase 1
Edwin Posadas, MD

3 total trials

What NCT06888102 shows while recruiting

NCT06888102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 54-participant average among 4 other High-risk Prostate Cancer trials with a reported enrollment target (63% lower).

The record links to 1 condition, with High-risk Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Neoadjuvant Epigenetic Therapy is the first listed.

NCT06888102 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06888102 about?

NCT06888102 is a clinical study titled "A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer". This is an open-label, non-randomized, exploratory platform protocol designed to assess the safety and antitumor activity of epigenetic therapies in participants with localized prostate cancer who are undergoing radical prostatectomy. The epigenetic therapy is intended to increase the sensitivity of...

What is the current status of trial NCT06888102?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-04. Estimated completion is 2029-10.

What conditions does trial NCT06888102 study?

This clinical trial studies the following conditions: High-risk Prostate Cancer.

What interventions are being tested in trial NCT06888102?

The interventions under investigation include: Neoadjuvant Epigenetic Therapy (DRUG).

Who is sponsoring clinical trial NCT06888102?

This trial is sponsored by Edwin Posadas, MD, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06888102 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for High-risk Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT06888102

Source: ClinicalTrials.gov NCT06888102, the US trial registry maintained by the National Library of Medicine. NCT06888102 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.